Histrelin is a synthetic nine-amino-acid peptide that mimics gonadotropin-releasing hormone (GnRH). Given continuously, it shuts down the pituitary signals that drive puberty and sex hormone production. This guide covers its structure, mechanism, approvals, trials and label warnings, with sources checked on November 17, 2026.
Quick answer: Histrelin is a prescription GnRH agonist peptide. Its current US label, Supprelin LA, covers children with central precocious puberty. An adult brand for advanced prostate cancer, Vantas, is listed as discontinued. Supprelin LA has no boxed warning. Its warnings include an early hormone surge, psychiatric events, seizures and severe skin reactions.
Vitrapep does not sell histrelin; this page is a reference summary of published research and regulatory information.
What is histrelin?
The Supprelin LA label calls histrelin acetate “a synthetic nonapeptide analog of the naturally occurring gonadotropin releasing hormone (GnRH)” (Supprelin LA label, 2025). A nonapeptide is a chain of nine amino acids. GnRH is the brain hormone that tells the pituitary gland to release reproductive hormones.
ChEBI, quoted in PubChem, lists its building blocks in order. They are pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl and N-ethylprolinamide residues. PubChem lists the formula as C66H86N18O12 and the molecular weight as 1,323.5 g/mol (PubChem CID 25077993). Our overview of peptide hormones explains how GnRH fits into the hormone system.
FDA’s orphan drug database lists marketing approval of Supprelin, from Roberts Pharmaceutical, on December 24, 1991 (FDA orphan database). Vantas was approved for prostate cancer on October 12, 2004. Drugs@FDA lists the original approval of Supprelin LA on May 3, 2007. Endo now holds both newer applications (Drugs@FDA).
Histrelin: key facts
| Fact | Detail |
|---|---|
| Structure type | Synthetic linear nonapeptide (nine amino acids), GnRH analog |
| Class | GnRH agonist |
| Molecular formula | C66H86N18O12 (free base) |
| Molecular weight | 1,323.5 g/mol |
| First FDA approval | December 24, 1991 (Supprelin) |
| Brand names (US) | Supprelin LA (2007, current); Vantas (2004, discontinued); Supprelin (1991) |
How does histrelin work?
Histrelin works through a paradox. It first switches the GnRH receptor on, then wears it out. The label states that Supprelin LA “is a GnRH agonist and an inhibitor of gonadotropin secretion when given continuously.” Continuous exposure “causes a reversible down-regulation of the GnRH receptors in the pituitary gland” (Supprelin LA label, 2025).
The label notes that histrelin first raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Pituitary desensitization then lowers both, which reduces sex steroid output from the ovaries or testes. The label says LH falls to prepubertal levels within 1 month of treatment. The same class includes leuprolide and triptorelin.
What is histrelin approved for?
The current Supprelin LA label has one indication. It is “indicated for the treatment of children with central precocious puberty (CPP)” (Supprelin LA label, 2025). Central precocious puberty is puberty that starts too early because the brain’s hormone signals switch on early.
Vantas had a separate adult indication. FDA’s 2004 approval letter covered its use “for the palliative treatment of advanced prostate cancer” (FDA approval letter, 2004). Drugs@FDA now lists Vantas as discontinued (Drugs@FDA).
What did the key trials show?
Central precocious puberty. The pivotal human trial was a phase 3, open-label, one-year study. It enrolled 36 children, 20 of whom had not had earlier GnRH agonist treatment. Peak LH after a stimulation test was a main outcome measure, along with estradiol in girls and testosterone in boys.
By month 1, peak LH had fallen sharply in both groups. Estradiol in previously untreated girls also fell significantly. The authors reported that “suppression was maintained throughout the study” (Eugster et al., 2007). The sponsor’s registry record, with 36 enrolled children, is NCT00779103. The label adds that LH suppression held in all children through month 12.
Advanced prostate cancer. The Vantas trial was an open-label, multicenter human study. Its registry record lists 138 enrolled men (NCT01697384). Of 134 men with week 4 results, 100% reached chemical castration, meaning very low testosterone. Suppression lasted through 52 weeks in more than 99% of patients (Schlegel et al., 2006).
What side effects does the label list?
The Supprelin LA label has no boxed warning. Its trial safety data cover 47 children. The most common reactions were local: the label lists bruising, pain, soreness, redness and swelling. A local site reaction was reported in 24 of 47 children (51.1%). Keloid or other scarring was also reported.
Less common reactions in trials included headache, mood swings, weight gain, breast tenderness and irregular menstrual bleeding. Post-marketing reports include emotional lability, depression with rare suicidal thoughts, seizures, pseudotumor cerebri and severe skin reactions (Supprelin LA label, 2025).
The warnings section covers these points:
- an initial agonist effect, with a temporary rise in estradiol or testosterone;
- psychiatric events;
- convulsions;
- severe skin reactions;
- pseudotumor cerebri (raised pressure around the brain); and
- monitoring with laboratory tests.
The label lists two contraindications: allergy to GnRH or GnRH agonist analogs, and pregnancy.
What is histrelin’s regulatory status, and how is it used in research?
Supprelin LA is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription, with Endo as the holder. FDA granted it orphan drug designation for central precocious puberty in 2005 (FDA orphan database). Vantas remains listed as discontinued.
Histrelin also appears in active prostate cancer trials as one hormone-therapy option among several. One example is the NRG Oncology Guidance trial, which lists histrelin as a drug in its androgen deprivation therapy arms (NCT05050084). The research summarized here is clinical and involves human patients.
Frequently asked questions about histrelin
Is histrelin a peptide?
Yes. It is a synthetic nonapeptide, a chain of nine amino acids modeled on natural GnRH.
When was histrelin first approved?
FDA records list marketing approval of the original Supprelin on December 24, 1991. Drugs@FDA lists the original approval of Supprelin LA on May 3, 2007.
Is Vantas still available?
Drugs@FDA lists Vantas, the prostate cancer brand, as discontinued.
How is histrelin different from leuprolide?
Both are GnRH agonists that suppress the pituitary with continuous exposure. They differ in their amino acid changes and in their approved products.
Does histrelin cause a hormone flare?
Yes, at first. The label warns of a temporary rise in estradiol or testosterone before suppression sets in.
What to know now
- Structure: synthetic GnRH nonapeptide; 1,323.5 g/mol.
- Approval: Supprelin 1991; Vantas 2004 (now discontinued); Supprelin LA 2007.
- Mechanism: GnRH agonist that down-regulates pituitary receptors with continuous exposure.
- Label: Supprelin LA for children with central precocious puberty.
- Evidence: LH suppression held through 12 months in the pediatric trial; 100% castrate testosterone at week 4 in the Vantas trial.
- Safety: no boxed warning; local reactions most common; psychiatric events and seizures are warned.
What we’re watching
Further Supprelin LA label revisions on DailyMed, last revised in September 2025. Cooperative-group prostate cancer trials on ClinicalTrials.gov that list histrelin among hormone options. Related guides: nafarelin, goserelin and leuprolide.